BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M

BridgeBio Pharma, Inc.

2025-Q2 EPS reported -$1.84 vs consensus -$0.86 ▼ miss (-113.9%)

Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.
Net loss attributable to common stockholders $181.9M ($0.95 EPS) vs $73.5M ($0.39 EPS) prior year.
As of Aug 1, 2025, 3,751 unique patient prescriptions for Attruby by 1,074 prescribers; launch accelerating.
Pipeline: FORTIFY (LGMD2I/R9) and CALIBRATE (ADH1) topline results expected fall 2025; PROPEL 3 (achondroplasia) early 2026.
Cash, cash equivalents and marketable securities $756.9M; raised $300M via royalty sale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.